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Unique autoantibody specificities are strongly associated with distinct clinical phenotypes, 
making autoantibodies useful for diagnosis and prognosis. To investigate the mechanisms 
underlying this striking association, we examined autoantigen expression in normal muscle 
and in muscle from patients with autoimmune myositis. Although myositis autoantigens are 
expressed at very low levels in control muscle, they are found at high levels in myositis 
muscle. Furthermore, increased autoantigen expression correlates with differentiation state, 
such that myositis autoantigen expression is increased in cells that have features of 
regenerating muscle cells. Consistent with this, we found that cultured myoblasts express 
high levels of autoantigens, which are strikingly down-regulated as cells differentiate into 
myotubes in vitro. These data strongly implicate regenerating muscle cells rather than 
mature myotubes as the source of ongoing antigen supply in autoimmune myositis. Myositis 
autoantigen expression is also markedly increased in several cancers known to be associated 
with autoimmune myositis, but not in their related normal tissues, demonstrating that 
tumor cells and undifferentiated myoblasts are antigenically similar. We propose that in 
cancer-associated myositis, an autoimmune response directed against cancer cross-reacts 
with regenerating muscle cells, enabling a feed-forward loop of tissue damage and antigen 
selection. Regulating pathways of antigen expression may provide unrecognized therapeutic 
opportunities in autoimmune diseases.
 
In systemic autoimmune diseases, there is a
strong association of autoantibodies against
specific autoantigens with unique clinical phe-
notypes, making autoantibodies useful diag-
nostically and prognostically (1, 2). For exam-
ple, Mi-2 autoantibodies are found in patients
with dermatomyositis (DM; reference 3); anti-
bodies recognizing several of the aminoacyl-
tRNA synthetases are found in patients with
myositis frequently associated with interstitial
lung disease (4, 5); autoantibodies recognizing
topoisomerase-1 are associated with diffuse
scleroderma and lung disease (6, 7); and au-
toantibodies recognizing dsDNA are diagnos-
tic of lupus (8, 9). In spite of such a strong as-
sociation with phenotype, these autoantigens
are ubiquitously expressed. Understanding the
mechanisms underlying this striking associa-
tion of targets of the immune response with
disease phenotype may identify pathways of
pathogenic and therapeutic relevance.
The antibody–phenotype association is rem-
iniscent of a variety of paraneoplastic auto-
immune syndromes, where autoantibody and
T cell responses target autoantigens that are
limited in expression to the inciting tumor
and the target organ (10, 11). For example, ex-
pression of the (neuro-oncological ventral an-
tigen) NOVA antigens is increased in tumor
tissue from patients with the clinically dis-
tinct paraneoplastic opsoclonus-myoclonus ataxia
(12), and expression of NOVA in adults is re-
stricted to neuronal tissue (13, 14). Similarly, a
high titer autoantibody response to the Hu an-
tigen is observed in patients with paraneoplas-
tic encephalomyelitis and sensory neuropathy,
and elevated levels of Hu target antigens are
expressed in small cell lung cancers and various
 
CORRESPONDENCE
Livia Casciola-Rosen: 
lcr@jhmi.edu
 
Abbreviations used: DM, der-
matomyositis; DNA-PK
 
cs
 
, cata-
lytic subunit of DNA-dependent 
protein kinase; HRS, histidyl 
tRNA synthetase; NCAM, 
neural cell adhesion molecule; 
NOVA, neuro-oncological 
ventral antigen; PARP, 
poly(ADP ribose polymerase); 
PCNA, proliferating cell nuclear 
antigen; PM, polymyositis; SLE, 
systemic lupus erythematosus. 
ENHANCED AUTOANTIGEN EXPRESSION IN MYOSITIS | Casciola-Rosen et al.
 
592
 
neuronal tissues (15–17). It remains unknown whether a
similar principle may underlie antigen selection and target
tissue specificity in systemic autoimmune rheumatic diseases,
in which autoantibodies are directed at proteins that are
widely expressed. In this regard, it is of interest that a variety
of tumor-associated autoantigens (not related to paraneoplas-
tic syndromes) may be oncogenic proteins up-regulated in
tumors (18–20).
Human idiopathic inflammatory myopathy (hereafter re-
ferred to as autoimmune myositis) provides an excellent
model with which to probe such autoantigen expression
for several reasons: (a) several myositis-specific autoantigens
have been well-defined (21); (b) unlike systemic lupus
erythematosus (SLE) and scleroderma (in which the target
tissues are inadequately defined or poorly accessible), muscle
is routinely obtained during diagnostic workup of autoim-
mune myositis and provides sufficient material for biochemi-
cal and histological analysis; and (c) an association between
autoimmune myositis and cancer has been demonstrated re-
peatedly (22–24). Although present for both DM and poly-
myositis (PM), the risk of cancer is substantially greater for
DM. Interestingly, the most frequent cancers associated with
both DM and PM are adenocarcinomas, being 
 
 
 
80% of
cancers in patients with cancer and DM and 70% of patients
with cancer and PM (24). Therefore, we examined autoanti-
gen expression in diseased tissue in human autoimmune my-
ositis and in several adenocarcinomas that are associated with
this autoimmune phenotype.
The studies yielded several striking insights that were not
predicted. Myositis autoantigens are expressed at low levels
in control muscle, but at high levels in myositis muscle. Fur-
thermore, increased autoantigen expression correlates with
differentiation state, such that myositis autoantigen expres-
sion is increased particularly in cells that have features of re-
generating muscle cells. Consistent with this in vivo obser-
vation, we found that cultured myoblasts express high levels
of autoantigens, which are strikingly down-regulated as cells
are differentiated into myotubes in vitro. These data strongly
implicate regenerating muscle cells rather than mature myo-
tubes as (a) targets of cytolytic attack in autoimmune myosi-
tis and (b) the source of ongoing antigen supply in this dis-
ease. By focusing damage onto those cells accomplishing
repair, a feed-forward loop is enabled, likely accounting for
the self-sustaining nature of the autoimmune response and
Figure 1. Myositis-specific autoantigens are expressed at low levels 
in control muscle and at high levels in myositis muscle. (A) Equal 
protein amounts of lysed human muscle biopsies, obtained from normal, 
DM, and PM patients, were immunoblotted with antibodies against the 
indicated antigens. The myositis-specific autoantigens (Mi-2, U1-70 kD, 
HRS, and DNA-PKcs) were expressed at high levels in myositis muscle. In 
contrast, levels of nonmyositis autoantigens and nonautoantigens were 
not increased in the myositis tissue. Of note, immunoblotted U1-70 kD was 
detected in two different forms in the tissue lysates (70 and 68 kD). These 
represent different phosphorylation states of U1-70 kD. Such altered forms 
can be detected in vitro; U1-70 kD in unincubated cell lysates migrates at 
70 kD, but after incubating the lysates at 37 C for 30 min with  -phos-
phatase, only the 68-kD form is blotted (not depicted). Black lines indicate 
that intervening lanes have been spliced out. (B) The immunoblots were 
scanned, and the data were quantitated by normalizing the immunoblotted 
level of each autoantigen relative to that of vinculin in the same lysate. In 
the set of immunoblots shown (representative of two to six blots per-
formed with each different lysed muscle biopsy), the vinculin data shown 
in the fifth panel was used to normalize all of the immunoblotted antigens 
except fodrin. The  -fodrin data were obtained using a different set of 
lysates, with its own matched vinculin blot (the latter is not depicted), and 
these vinculin values were used to normalize the  -fodrin data. 
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injury that is a general feature of autoimmune diseases. Inter-
estingly, autoantigen expression is also markedly increased in
several cancers associated with autoimmune myositis, but
not in the related normal tissues, demonstrating that tumor
cells and undifferentiated myoblasts are antigenically similar,
and suggesting a mechanism for disease initiation and propa-
gation in autoimmune myositis.
 
RESULTS
Myositis-specific autoantigens are expressed at low levels in 
control muscle, but at high levels in myositis muscle
 
The autoantigens frequently targeted in human autoimmune
myositis have been well defined. These include histidyl
tRNA synthetase (HRS/Jo-1; 10–20% of patients), Mi-2
(15–30% of DM patients), U1-70kD (5–20% of patients),
and Ku/the catalytic subunit of DNA-dependent protein ki-
nase (DNA-PK
 
cs
 
; 5–20% of patients). It is noteworthy that
even the most common individual established autoantibodies
are found in less than one third of myositis patients (25–28).
Several of these antigens (e.g., HRS and Mi-2) are myositis
specific (29), whereas others may be targeted in myositis as
well as other systemic autoimmune syndromes (e.g., U1-
70kD and DNA-PK
 
cs
 
 are targeted in lupus, myositis, and
overlap syndromes; references 30, 31). To define whether
autoantigen expression in myositis muscle is altered com-
pared with control muscle, biochemical levels of autoanti-
gens in equal protein amounts of detergent lysates of human
muscle biopsies were determined by immunoblotting (Fig. 1
A). In preliminary studies, we showed that vinculin expres-
sion was constant in equal protein amounts of the different
muscle biopsies (Fig. 1 A). To facilitate quantitative bio-
chemical analysis of human biopsies in which there can
be significant interindividual variation, we analyzed lysates
made from eight different normal biopsies, six patients with
DM, and nine patients with PM, and normalized protein ex-
pression to vinculin as a loading control. Expression levels of
Mi-2, U1-70kD, HRS, and DNA-PK
 
cs
 
 were low in control
muscle biopsy lysates (Fig. 1 A, lanes 1–4), but were strik-
ingly increased in patients with autoimmune myositis (U1-
70 kD: 34-fold increase, P 
 
  
 
0.002; HRS: 4.3-fold increase,
P 
 
  
 
0.045; and DNA-PK
 
cs
 
: 6.9-fold increase, P 
 
  
 
0.006).
Mi-2 levels were increased exclusively in DM biopsies
(mean of 10-fold increase, P 
 
 
 
 0.045), but not in PM biop-
sies (1.2-fold, P 
 
  
 
0.9; Fig. 1 B), a finding of particular in-
terest because Mi-2 autoantibodies are found selectively in
DM (3, 4). Of note, levels of control nonautoantigens (vin-
culin, elongation factor 1
 
 
 
, Bid, and p115) and nonmyositis
autoantigen molecules (
 
 
 
-fodrin, golgin 160, topoisomerase
I, and B23) were not significantly different in muscle biopsy
lysates made from normals or patients with myositis (Fig. 1 B
and not depicted).
 
Autoantigen expression is increased in muscle cells 
in myositis muscle
 
Because immunoblotting detects antigen levels in lysates
comprising both muscle cells and immigrant inflammatory
cell populations, we examined autoantigen expression in
control and inflamed muscle by immunocytochemistry when
appropriate reagents were available. Staining of HRS with
affinity-purified polyclonal antipeptide antibodies in control
muscle showed diffuse low-level staining in all cells (Fig. 2,
A); staining was completely competed away with the cog-
nate peptide, but not with an irrelevant peptide (not de-
picted). In PM and DM, increased staining of HRS was evi-
dent; this staining was restricted to the cytoplasm of muscle
cells and was completely competed by specific peptide (Fig.
2, B and C, and not depicted). Similarly, low levels of
DNA-PK
 
cs
 
 and Ku70 were demonstrable in control muscle
biopsies (Fig. 2, D and G). Levels of DNA-PK
 
cs
 
 and Ku70
were increased in the nuclei of both PM and DM biopsies
(Fig. 2, E, F, H, and I, respectively). At higher magnifica-
tions, it was clear that these increased levels of DNA-PK
 
cs
 
were associated with muscle cell nuclei as well as inflamma-
tory cells (see Fig. 4).
 
Muscle cell regeneration is a prominent feature in myositis
 
Several different markers of muscle cell regeneration were
used to interrogate the amount of regeneration in muscle bi-
opsies. Both immunohistochemical analysis and immuno-
blotting were used to quantitate the regeneration activity in
Figure 2. DNA-PKcs, HRS, and Ku70 staining is increased in myo-
cytes in DM and PM muscle compared with normal muscle. (A–C) 
Normal (A) and PM (B and C) muscle biopsies were stained using affinity-
purified rabbit anti-HRS polyclonal antibody in the absence (A and B) or 
presence (C) of competing peptide. A faint sarcoplasmic pattern was noted 
in normal muscle (A), with increased staining being detected in the PM 
biopsy (B). The staining was abolished upon preincubation of the antibody 
with specific (immunizing) peptide (C), but not with a nonspecific peptide 
(not depicted). (D–I) Normal (D and G), PM (E and H), and DM (F and I) 
biopsies were stained using monoclonal antibodies against DNA-PKcs
(D–F) or Ku70 (G–I). Normal biopsies showed low levels of nuclear stain-
ing. The number and intensity of brown positive nuclei was significantly 
increased in DM and PM biopsies. All panels have a magnification of 40. 
The data shown are representative fields from multiple different normals 
and patients. A, n   5; B and C, n   3; D, n   4; E, n   12; and F, n   4. 
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these biopsies. Regenerating cells (positive for neural cell ad-
hesion molecule [NCAM; reference 32], neonatal myosin
heavy chain [33], or developmental myosin heavy chain ex-
pression [34]) were rare in control biopsies, but were fre-
quent in biopsies from patients with either DM or PM (Fig.
3, A–F, and not depicted). NCAM-positive fibers were sig-
nificantly increased in DM (35.5 
 
 
 
 10.1 vs. 5.2 
 
 
 
 1.1,
mean 
 
 
 
 SE; DM vs. normal: P 
 
  
 
0.05) and PM (26.9 
 
 
 
 6.9
vs. 5.2 
 
 
 
 1.1, mean 
 
 
 
 SE; PM vs. normal, P 
 
  
 
0.05) (Fig. 3,
G). The difference between PM and DM was not signifi-
cant. Normal biopsies showed small numbers of NCAM-
positive fibers, which were only present in a few fields.
NCAM staining was undetectable by immunoblotting in
control biopsies (
 
n
 
 
 
  
 
4), but was positive (in some cases
markedly so) in 75% (
 
n
 
 
 
  
 
8) of myositis biopsies (Fig. 3, H;
P 
 
  
 
0.013; Fisher’s exact test). The pattern of staining of all
regeneration markers was similar to the primary histological
patterns noted in each phenotype. Thus, regenerating cells
were particularly prominent with a perifascicular pattern in
DM and an intrafascicular pattern in PM.
Interestingly, autoantigen levels were highest in cells
with the morphologic features of regeneration; staining of
serial DM or PM muscle sections with antibodies to DNA-
PK
 
cs
 
 and neonatal myosin heavy chain showed strong stain-
ing of DNA-PK
 
cs
 
 in regenerating cells (Fig. 4 and not de-
picted). Strikingly, in DM biopsies (where regeneration has
a predominantly perifascicular distribution), areas devoid of
regenerating muscle cells (neonatal myosin heavy chain
negative) also did not stain with the anti–DNA-PK
 
cs
 
 anti-
body. Similar findings were made for HRS in which high-
est levels of expression were observed in regenerating cells
(Fig. 4 B, data for NCAM and HRS staining). We were
unable to examine Mi-2 expression in normal and myositis
muscle by immunohistochemistry due to the lack of avail-
ability of appropriate antibodies. This pattern of absent ex-
pression in control muscle with marked increases in expres-
sion in myositis muscle is strikingly reminiscent of MHC
class I (35–37). When we examined MHC class I expres-
sion in normal and myositis muscle, cells expressing regen-
eration markers (neonatal myosin heavy chain) also ex-
Figure 3. NCAM and neonatal MHC-positive muscle fibers are rare 
in controls, but frequent in muscle biopsies from DM and PM 
patients. (A–F) Normal (A and D), PM (B and E), and DM (C and F) biopsies 
were stained using antibodies against NCAM (A–C) or neonatal myosin 
heavy chain (nMHC) (D–F). NCAM and nMHC-positive fibers were rarely 
detected in normal muscle, but were frequently seen in PM and DM biop-
sies. Positive fibers were enriched in perifascicular areas of DM (C and F) 
and were spread throughout the fascicle in PM (B and E). The data shown 
are representative fields from multiple different normals and patients; 
normal, n   5; DM, n   11; and PM, n   11. All fields have a magnifica-
tion of 40. (G) To quantitate the data, the number of NCAM-positive fibers 
in up to five different areas of the biopsy were counted, and the average 
number of positive fibers per field was calculated. Normal biopsies occa-
sionally showed a small number of NCAM-positive fibers (not depicted in 
A). (H) Equal protein amounts of muscle biopsy lysates obtained from 
normal, DM, and PM patients were immunoblotted with antibody against 
NCAM. Black lines indicate that intervening lanes have been spliced out. 
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pressed high levels of MHC class I as well as DNA-PK
 
cs
 
(unpublished data). Together, these data demonstrate that
autoantigen expression is particularly enhanced in regener-
ating muscle cells.
 
Autoantigen expression changes significantly during in vitro 
differentiation of myoblasts
 
Because (a) the expression level of several myositis autoantigens
was increased in myositis tissue compared with controls, (b) the
number of muscle cells expressing markers of regeneration was
increased in myositis, and (c) there was evidence supporting
the preferential expression of increased antigen levels in these
less-differentiated cells, we sought to examine the effect of dif-
ferentiation on autoantigen expression in primary human mus-
cle cells differentiating in vitro. Equal protein amounts of mus-
cle cell lysates were studied at increasing times after initiation of
differentiation, and differentiation state was confirmed by ex-
amining levels of NCAM and adult heavy chain myosin ex-
pression. Thus, high levels of NCAM and undetectable levels
of adult myosin heavy chain were found in the cultured myo-
blasts, whereas day-14 myotubes had undetectable levels of
NCAM and high levels of adult myosin heavy chain (Fig. 5 A).
These findings were consistent with the predicted differentia-
tion status of the cells at both points.
Levels of Mi-2, poly(ADP ribose polymerase) (PARP),
U1-70kD, DNA-PK
 
cs
 
, and HRS were high in undifferenti-
ated cells, and diminished as myotubes formed over time.
In contrast, levels of vinculin and the vesicle marker p115
remained unchanged (Fig. 5, B and C). The expression lev-
els of nonmyositis autoantigens were variably affected in
this in vitro differentiation assay. Although some antigen
levels remained unchanged (B23 and 
 
 
 
-fodrin), others had
a similar pattern to myositis antigens (i.e., high in myoblasts
and low in myotubes). Examples of this pattern include to-
poisomerase I, GM 130, and RNA polymerase II (unpub-
lished data).
We also examined the expression of myositis autoanti-
gens in proliferating and quiescent vascular smooth muscle
cells (Fig. 6). We initially confirmed the proliferative/differ-
entiation state of the cell populations using proliferating cell
nuclear antigen (PCNA) expression as a marker of cell pro-
liferation, and 
 
 
 
-smooth muscle actin as a marker of the dif-
ferentiated phenotype. PCNA expression was robust in pro-
liferating cells, but absent in quiescent cells (ratio of 84.5:1).
In contrast, 
 
 
 
-smooth muscle actin was expressed at low
levels in proliferating cells, but was increased in quiescent
cells (ratio of 1:25). Interestingly, the relative expression of
Mi-2 (normalized to vinculin) in proliferating vascular
smooth muscle cells was decreased 5.2-fold compared with
that in skeletal muscle myoblasts (unpublished data). Fur-
thermore, unlike skeletal muscle cells, Mi-2 and DNA-PK
 
cs
 
levels were not increased in proliferating over quiescent
cells when normalized for protein loading (Fig. 6). To-
gether, these data strongly indicate that myositis autoanti-
gens are differentially expressed during muscle cell differen-
tiation and that this enhanced expression is not a general
property of proliferating cells. Therefore, the data focus at-
tention on the regenerating skeletal muscle cell as the
source of antigen that feeds the ongoing immune response
in myositis.
Figure 4. High levels of DNA-PKcs and HRS staining are found in 
regenerating myocytes in DM muscle. (A) Serial DM muscle biopsy 
sections were stained with antibodies against neonatal myosin heavy 
chain or DNA-PKcs. (left and center) Both antibodies stained an overlap-
ping subset of cells in serial sections with a striking perifascicular pattern 
characteristic of DM. Note that areas within the fascicle are not stained 
with either antibody. (right) Higher magnification showed increased DNA-
PKcs staining in many muscle cell nuclei. (B) A separate set of serial DM 
muscle biopsy sections was stained with antibodies against NCAM (mono-
clonal) or HRS (affinity-purified anti-HRS polyclonal antibody). These 
antibodies stained an overlapping subset of cells on the serial sections. (A 
and B) Unless otherwise indicated, all panels have a magnification of 5. 
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Myositis autoantigens are frequently expressed at low levels 
in a variety of normal tissues, but at increased levels 
in tumors
 
Because the association of myositis with a wide variety of
malignancies has been repeatedly demonstrated (22–24), we
evaluated Mi-2, DNA-PK
 
cs
 
, HRS, and vinculin (a loading
control) expression by immunoblotting detergent lysates of
several tumors known to be associated with myositis, and
their corresponding normal tissues. Initial studies demon-
strated that the very low levels of Mi-2 expression in normal
muscle were representative of all other normal primary tis-
sues tested; thus, Mi-2 was not detectable in normal adult
human breast, liver, thymus, and lung (Figs. 1 A and 7 A). In
contrast, Mi-2 was expressed at high levels in breast and lung
adenocarcinomas (Fig. 7 B), as well as in hepatocellular car-
cinoma (not depicted). Mean Mi-2 levels (normalized to
vinculin) were elevated 53-fold and 11-fold in breast and
lung adenocarcinomas, respectively, relative to the corre-
sponding normal tissue. Similarly, DNA-PK
 
cs
 
 was expressed
at very low levels in normal breast and lung tissue, but was
increased in the corresponding adenocarcinomas. An identi-
cal pattern was observed for HRS expression in normal
breast and breast cancers (Fig. 7 B, left). The data for HRS
expression in lung and lung cancers was distinct and interest-
ing. HRS expression in normal lung was higher than that
observed in equal amounts of other normal tissues and there
Figure 5. Autoantigen expression is high in cultured myoblasts and 
low in differentiated myotubes. Primary human myoblasts were differ-
entiated to myotubes over 14 d as described in Materials and methods. 
The levels of expressed antigens were assessed by immunoblotting equal 
protein amounts of the lysates harvested at each time point. (A) Lysates 
made from cells harvested at day 0 (myoblasts) and day 14 of differentia-
tion (myotubes) were immunoblotted with antibodies against NCAM and 
myosin. Expression of NCAM and myosin in myoblasts and myotubes, 
respectively, confirmed the differentiation status of the cell cultures. (B) 
Lysates made from cells harvested at various times during the 14 d 
differentiation period were immunoblotted with the indicated antibodies. 
Levels of autoantigen expression were decreased in myotubes; in contrast, 
the expression of nonautoantigens remained constant. (C) The data 
obtained in B was scanned and quantitated. For each antigen, the 
myoblast level (day 0 of differentiation) was assigned the value 100%, and 
the antigen levels at each time point were expressed relative to this.
Figure 6. Myositis-specific autoantigen levels are not increased in 
proliferating versus quiescent aortic smooth muscle cells. Proliferating 
(P) or quiescent (Q) human aortic smooth muscle cells were prepared as 
described Materials and methods. 3   104 cells were electrophoresed in 
each gel lane. Lysates were immunoblotted with the indicated antibodies. 
The data were scanned, and the levels of each antigen in the proliferating 
cultures was expressed relative to that in the quiescent culture (P/Q ratio). 
PCNA and  -smooth muscle actin were expressed at high levels in the 
proliferating and quiescent cultures, respectively. DNA-PKcs and Mi-2 
expression were not significantly different in proliferating and quiescent cells. 
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was a variable and modest increase in HRS expression in
lung cancers (Fig. 7 B).
 
DISCUSSION
 
Although autoantigens in systemic autoimmune diseases are
ubiquitously expressed molecules that function in conserved,
nontissue-specific pathways, the expression of such molecules
in the relevant target tissues in humans has not been defined
previously. In these studies, we have examined autoantigen
expression in normal and diseased target tissue in human au-
toimmune myositis, and have made the unexpected finding
that myositis autoantigens are expressed at very low levels in
control muscle. Therefore, it is unlikely that initiation and
propagation of the immune response to myositis antigens oc-
curs in normal, unperturbed muscle. In contrast, myositis au-
toantigens are expressed at high levels in myositis muscle,
where the enhanced autoantigen expression is found in mus-
cle cells that express markers of an immature phenotype. Fur-
thermore, such changes in autoantigen expression can be re-
capitulated during in vitro differentiation of human myoblasts
into myotubes. Studies on proliferating and quiescent smooth
muscle cells indicate that the enhanced expression of myositis
autoantigens is not a general marker of proliferating cells.
This suggests a new paradigm for disease propagation in myo-
sitis that focuses, for the first time, on regenerating cells as the
source of ongoing antigen drive.
Muscle cell damage and regeneration occur in both PM
and DM, but the pathologic phenotypes are generally distin-
guishable, based in part on the pattern of muscle involve-
ment (perifascicular vs. intrafascicular), and the relationship
to blood vessel involvement (38). Interestingly, the expres-
sion of Mi-2, an autoantigen targeted specifically in DM, is
significantly increased (
 
 
 
10-fold) only in muscle biopsies
from patients with DM, and not PM. This phenotype-spe-
cific expression of Mi-2 is of particular interest because it
demonstrates that a DM-specific pattern of autoantigen ex-
pression correlates with the DM-specific autoantibody re-
sponse. Because both DM and PM have similar numbers of
regenerating cells, this enhanced expression of Mi-2 cannot
be due to expression in all dividing cells. In contrast with
Mi-2, the expression of U1-70kD (an autoantigen targeted
in patients with DM and PM as well as overlap syndromes) is
increased equally in muscle from patients with PM and DM.
Expression of 
 
 
 
-fodrin (specifically targeted in Sjogren’s syn-
drome; references 39–41), golgin-160 (targeted in lupus/
Sjogren’s syndrome; reference 42) and B23 (targeted in
scleroderma and SLE; references 43, 44) was not significantly
different in normal and myositis muscle. The augmented ex-
pression in myositis muscle of several autoantigens targeted
specifically in myositis, but not other systemic autoimmune
syndromes, further supports a role for distinct states of the
target tissue in shaping the specificity of the phenotype-spe-
cific autoantibody response.
The preferential expression of myositis autoantigens in
regenerating muscle cells may also account for the well-
defined, patchy histologic changes in myositis, where areas
of muscle damage, inflammation, and regeneration can be
found adjacent to areas that are apparently histologically nor-
mal (45). Similar patchy pathologic changes are found in
several other autoimmune diseases, raising the possibility that
generation of disease-specific autoantibodies in systemic au-
toimmune syndromes reflects distinct antigen expression pat-
terns in each unique propagating microenvironment. It will
be important to define whether regenerating cells in differ-
ent tissues (e.g., lung, skin, synovium, blood vessel) exhibit
unique patterns of autoantigen expression and to elucidate
the mechanisms that underlie these differences in expression.
The studies reported here do not identify the site of initi-
ation of the immune response in myositis. It is possible that
Figure 7. Myositis autoantigens are frequently expressed at low 
levels in normal tissue, but at increased levels in tumors. (A and B) 
Lysates were made from the indicated normal and tumorous human 
tissues. Equal protein amounts were electrophoresed in each gel lane on 
10% SDS-polyacrylamide gels, and immunoblotted with a human serum 
monospecific for Mi-2, a polyclonal anti-HRS antibody, or monoclonal 
antibodies against DNA-PKcs and vinculin. The data shown are representa-
tive of those obtained from 8–10 different cancer biopsies of each type in 
two to three separate experiments. Black lines indicate that intervening 
lanes have been spliced out. (B) Mi-2 levels were elevated in 10/10 (breast) 
and 9/10 (lung) cancer tissue lysates; DNA-PKcs expression was increased in 
9/10 (breast) and 8/8 (lung) cancer tissue lysates, and HRS levels were ele-
vated in 3/3 (breast) cancer tissue lysates. HRS was expressed fairly robustly 
in normal lung with only small increases (if any) detected in cancerous lung. 
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unique forms of proinflammatory muscle injury inducing
significant muscle regeneration may initiate autoimmunity
directly in muscle. In particular, it is possible that autoanti-
gen overexpression in diseased tissue in DM or PM might be
associated with increased DNA damage, leading to up-regu-
lation of repair proteins. This would be consistent with in-
creased expression of DNA-PK
 
cs
 
, PARP, and Mi-2 in re-
generating cells, and with previous observations that myositis
is associated with autoantibodies to proteins involved in
DNA repair (46).
Our studies also demonstrate that the antigenic finger-
print of tumors associated with myositis strongly resembles
that of regenerating muscle cells in myositis, raising the inter-
esting possibility that the immune response in myositis is ini-
tiated as an antitumor response. The high level expression of
Mi-2, DNA-PK
 
cs
 
, and HRS in adenocarcinomas of the lung
and breast, in contrast with absent expression in normal liver,
muscle, and breast (all three antigens), and normal lung (for
Mi-2 and DNA-PK
 
cs
 
 only) is reminiscent of the restricted ex-
pression of Ri/NOVA autoantigens to tumors and specific
areas of the central nervous system that become targets for
immune-mediated damage (for review see reference 10). The
major difference is that autoantigen expression in the target
tissue in myositis is not constitutive, but is induced in regen-
erating muscle cells. The observation that levels of HRS may
be increased in normal lung compared with other tissues is of
potential interest because this autoantibody response is associ-
ated with interstitial lung disease in myositis (47, 48).
 
Model of cancer-associated myositis
 
A variety of tumors, but not normal healthy tissue, express
high levels of myositis autoantigens. As with the PND
model (10, 11), in which autoantigen expression in tumors is
almost universal but immune responses occur in only a mi-
nority of patients (
 
 
 
15%), we propose that an effective,
adaptive cytolytic antitumor immune response develops in-
frequently and is directed against a group of antigens shared
with immature or regenerating muscle cells. Because normal
muscle contains very low levels of myositis autoantigens at
baseline and does not express MHC class I (49), healthy
muscle is not targeted by the antitumor immune response. In
the setting of nonspecific muscle injury (e.g., trauma or
overuse, viral infection, drugs, or DNA damage), increased
numbers of regenerating cells that express myositis autoanti-
gens at high levels are induced, providing the target to focus
antigen-specific immune responses onto muscle. Of particu-
lar relevance here is the observation that MHC class I ex-
pression is strikingly elevated in the context of muscle dam-
age (50), particularly on regenerating cells (unpublished
data). Once muscle injury has occurred in the setting of a cy-
tolytic immune response that cross-reacts with regenerating
muscle cells, a feed-forward cycle of injury is induced that is
focused at regions of muscle regeneration. The uniform sus-
ceptibility of myositis autoantigens to cleavage by granzyme
B (51), and the marked enrichment of perforin- and
granzyme-expressing activated CD8
 
 
 
 T cells in DM and PM
muscle (52) is of great interest in this regard. Direct demon-
stration of myositis antigen-reactive CD8
 
 
 
 T cells is a major
priority. In this construct, muscle regeneration could be
viewed as a cause, as well as a consequence of, muscle dam-
age. Adjacent noninjured muscle (not expressing significant
levels of autoantigens or MHC class I) would not be suscep-
tible to damage, potentially explaining the striking observa-
tion that nonaffected areas of muscle exist in myositis imme-
diately adjacent to areas of damage and regeneration (45).
The kinetic relationship of an antitumor immune re-
sponse and development of myositis remain unknown. Re-
cent studies in lupus have demonstrated that initiation of an
autoimmune response and development of the diagnostic
phenotype are frequently separated in time, sometimes for a
period of years (53). In these studies, development of an an-
tinuclear antibody and antiphospholipid antibodies generally
predated the development of symptoms of SLE, which cor-
related with the onset of an autoantibody response directed
against the spliceosome (53). It is possible that a similar sepa-
ration of initiation of the immune response and development
of the diagnostic phenotype occurs in myositis, the latter
event being stimulated by nonspecific muscle damage occur-
ring in the setting of a prior antitumor immune response.
In summary, the studies reported here identify several
previously unrecognized principles relevant to the initiation
and propagation of autoimmune myositis and potentially
other autoimmune rheumatic diseases. First, mature, healthy
tissue may not be the primary target of autoimmunity, but
rather injured and repairing tissue in which stem cells or dif-
ferentiating cells are replacing injured cells. Second, the phe-
notype-specific antigen fingerprint and phenotype-specific
autoantibody response are related. Third, immature muscle
cells and tumor cells share similarities in their antigenic com-
position, which differs from that present in mature, differen-
tiated tissues. Although available therapies frequently target
the immune effector components of autoimmune diseases,
inhibiting antigen expression might be of even greater thera-
peutic relevance. We propose that regulating cell differentia-
tion and/or pathways responsible for unique antigen expres-
sion patterns in target tissue will provide unique therapeutic
opportunities in autoimmune diseases.
 
MATERIALS AND METHODS
 
Human tissue and disease status. 
 
All studies on human materials were
performed on samples provided in compliance with Institutional Review
Board and Health Insurance Portability And Accountability Act regulations.
Muscle biopsies were obtained from patients seen at the Neuromuscular
Clinic at Johns Hopkins Hospital and at the Armed Forces Institute of Pa-
thology. All other human tissues were obtained from the Departments of
Surgery or Pathology at the Johns Hopkins Medical Institutions. Research
tissue samples were obtained within 1 h of surgical resection. The surgical
procedures were performed for patient management, and the research tissue
samples were in excess of tissue required for routine diagnostic purposes.
Muscle biopsies were obtained from six patients with DM, nine patients with
PM, and eight controls whose biopsies were histologically normal. Histo-
logic criteria for the muscle biopsies identified as consistent with DM
included perifascicular atrophy; myofiber degeneration, regeneration, and
necrosis; and perivascular inflammation with or without endomysial inflam- 
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mation. Histologic criteria for the muscle biopsies consistent with PM in-
cluded demonstration of primary endomysial inflammation defined as
chronic mononuclear inflammatory cells surrounding and/or invading nor-
mal-appearing myofibers, as well as evidence of myofiber degeneration, re-
generation, and necrosis. The breast cancer biopsies represented nine cases of
ductal adenocarcinoma (all grade 2 or 3) and one case of lobular adenocarci-
noma. Normal human mammary tissue was obtained as discarded material
from reduction mammoplasty, and was treated as described previously (54).
The 10 lung cancer biopsies were all cases of pulmonary adenocarcinoma.
Cell culture and differentiation.  Normal human skeletal muscle cells
from a single donor (Clonetics) were cultured as described previously (55).
When the cultures were  80% confluent, the cells were induced to differ-
entiate into myotubes by replacing the growth medium with medium A
containing DMEM, 2% horse serum, and L-glutamine, and growing the
cells for a further 2 wk without subculturing. Human aortic smooth muscle
cells were cultured and differentiated exactly as described previously (56).
Immunoblotting of antigens in cultured cells.  Biochemical levels of
antigens expressed in myoblasts and myotubes were assessed by harvesting
myoblasts immediately after changing into medium A (day 0) and at days 2,
5, 9, and 14 (for HRS/Jo-1) or days 1, 3, 7, 11, and 14 (all other antigens are
shown). Culture dishes were placed on ice, and the cells were washed twice
in PBS and lysed in lysis buffer containing 1% Nonidet P-40, 20 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM EDTA, and protease inhibitors (57). 70  g of
each sample was electrophoresed on 10% SDS-polyacrylamide gels, trans-
ferred to nitrocellulose membrane and immunoblotted with patient sera
monospecific for Mi-2, PARP, U1-70 kD, or HRS, or monoclonal anti-
bodies against vinculin (Sigma-Aldrich), DNA-PKcs (Oncogene Research
Products), p115 (Transduction Labs), NCAM (Serotec), and myosin (Sigma-
Aldrich) as described previously (58, 59). Time course experiments were
performed at least three times with similar results for each antigen on every
occasion. Biochemical levels of antigens expressed in aortic smooth muscle
cells were assessed by harvesting the cells before or after differentiation, when
the cells were proliferating or quiescent, respectively. 3   104 cells were
loaded in each gel lane. Immunoblots were performed as described before. In
addition, immunoblots were performed with monoclonal antibodies against
 -smooth muscle actin (Sigma-Aldrich) and PCNA (BD Biosciences).
Immunoblotting and quantitation of antigens in lysates made from
biopsies of human muscle, as well as lung and breast adenocarci-
nomas. Biopsy pieces were weighed, placed in ice-cold Petri dishes (with
all subsequent steps being performed at 4 C), cut into small pieces, and trans-
ferred to a glass Kontes homogenizer containing lysis buffer ( 10–20  l/mg
tissue) and protease inhibitors. The tissue was dounced with 20 strokes, the
homogenate was centrifuged (16,000 g, 4 C, 10 min), and the supernatant
was used for protein assay and to make gel samples. Equal amounts of lysate
protein were electrophoresed in each gel lane, transferred to nitrocellulose,
and immunoblotted as described before. Antibodies used to immunoblot
Mi-2, U1-70 kD, DNA-PKcs, and vinculin were as described before. HRS
and topoisomerase I were immunoblotted with polyclonal antibodies raised
against purified full-length HRS or an NH2-terminal topoisomerase I pep-
tide, respectively. Fodrin and elongation factor 1  were detected using
monoclonal antibodies purchased from Upstate Biotechnology and Chemi-
con International, respectively. In those cases where patient sera were used
to immunoblot human muscle biopsy lysates (Mi-2 and U1-70 kD), great
care was taken to ensure that those parts of the transfers containing human
immunoglobulins were discarded to eliminate any cross-reactivity with the
horseradish peroxidase–labeled anti–human IgG used as a secondary anti-
body. Representative examples of immunoblots are shown in Fig. 1 A. The
immunoblots were quantified by densitometry, and the data were normal-
ized for each antigen relative to vinculin blotted in the same lysate. The
NCSS/PASS statistical analysis program (NCSS statistical software) was used
for appropriate statistical analyses and to create box plots.
Immunohistochemistry. Frozen muscle biopsy sections (5–8 microns)
were fixed in acetone and endogenous peroxidase activity was blocked by
applying hydrogen peroxide at room temperature for 10 min as described
previously (55). Sections were incubated overnight at 4 C in a humidified
chamber with the following primary antibodies: mouse anti–rabbit neonatal
myosin heavy chain (cross reacts with human; Novo castra); mouse anti–
human DNA-PKcs, mouse anti–human Ku70 (Abcam Inc.), mouse anti–
human NCAM (Becton Dickinson), and rabbit anti–human HRS (raised
against a peptide at the COOH terminus of HRS and affinity-purified using
the coupled immunizing peptide). The sections were washed in Tris-buff-
ered saline and incubated with appropriate secondary antibodies conjugated
with horseradish peroxidase for 1 h at room temperature. Staining was visu-
alized after incubating with 3,3-diaminobenzidine and all sections were
counterstained with Mayers’ hematoxylin. Negative controls were per-
formed either by incubating with isotype matched antibody, by omitting
the primary antibody, or (in the case of HRS) by preincubating the affinity-
purified primary antibody with the HRS peptide used for immunization.
Quantitation of regenerating muscle fibers in muscle biopsies.
Several markers of regenerating muscle cells (NCAM, neonatal myosin
heavy chain, developmental myosin heavy chain) were used in immunohis-
tochemistry as described before. We quantified NCAM-positive muscle fi-
bers in PM (n   10), DM (n   7), and normal (n   5) muscle biopsies.
Frozen muscle sections were stained with anti-NCAM antibody as de-
scribed before. The intensity and pattern of NCAM reactivity (Figs. 3 and
4, visualized as a brown color) varied among positive fibers, with staining
being observed in small and large fibers. Some fibers showed both cell sur-
face and intense cytoplasmic staining, whereas others stained strongly at the
cell surface but diffusely in the cytoplasm. The number of NCAM-positive
fibers in five nonoverlapping, randomly selected areas of each biopsy was
counted using a 10  objective on an Axioscope microscope (Carl Zeiss
MicroImaging, Inc.). The average number of positive fibers per field was
determined for each group, and statistical significance was calculated using
the Student’s t test. Similar data was obtained with neonatal myosin heavy
chain and developmental myosin heavy chain (unpublished data).
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